While chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the treatment landscape for patients with B-cell malignancies, their efficacy against solid tumors has been nominal. We are focused on using strategic gene engineering to identify and overcome intrinsic and extrinsic regulators of CAR-T resistance in patients with solid tumors.